8wd0

Publication Abstract from PubMed

Erianin, a natural compound derived from Dendrobium, has shown significant anticancer properties against a wide range of cancer cells. Despite the identification of multiple mechanisms of action for erianin, none of these mechanisms fully account for its broad-spectrum effect. In this study, we aimed to identify the cellular target and underlying mechanism responsible for the broad-spectrum antitumor effects of erianin. We found that erianin effectively inhibited tubulin polymerization in cancer cells and purified tubulin. Through competition binding assays and X-ray crystallography, it was revealed that erianin bound to the colchicine site of beta-tubulin. Importantly, the X-ray crystal structure of the tubulin-erianin complex was solved, providing clear insight into the orientation and position of erianin in the colchicine-binding site. Erianin showed activity against paclitaxel-resistant cells, evidenced by G2/M cell cycle arrest, apoptosis-related PARP and Caspase-3 cleavage, and in vivo xenograft studies. The study concluded that erianin bound reversibly to the colchicine site of beta-tubulin, inhibited tubulin polymerization, and displayed anticancer activity against paclitaxel-resistant cells, offering valuable insights for further exploration as potential anticancer agents.

The cytotoxic natural compound erianin binds to colchicine site of beta-tubulin and overcomes taxane resistance.,Yan W, Zhou Y, Yuan X, Bai P, Tang M, Chen L, Wei H, Yang J Bioorg Chem. 2024 Jun 17;150:107569. doi: 10.1016/j.bioorg.2024.107569. PMID:38905886^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.